https://www.clinicaltrialsarena.com/analyst-comment/esmo25-relacorilant-shows-sustained-efficacy-in-parp-exposed-resistant-ovarian-cancer/
Most recurrent ovarian cancer cases arise in patients previously treated with PARP inhibitors making these relacorilant results noteworthy.
esmorelacorilantshowssustainedefficacy